Table 1 Population characteristics and viral suppression levels
Variable | Overalla N = 1946 | < 50 copies/mLb N = 1305 (67.1%) | < 1000 copies/mLb N = 1546 (79.4%) | ≥ 1000 copies/mLb N = 400 (20.6%) | p-value* |
|---|---|---|---|---|---|
Age in year, median (IQR) | 41 (34–50) | 41 (34–50) | 42 (34–50) | 39 (33–49) | < 0.001 |
Year of cART start, median (IQR) | 2012 (2009–2014) | 2012 (2009–2014) | 2012 (2009–2014) | 2011 (2008–2013) | < 0.001 |
Duration on cART in month, median (IQR) | 48 (24–48) | 48 (24–48) | 48 (24–48) | 48 (36–48) | 0.001 |
Gender, n (%) | |||||
Male | 573 (29.4) | 352 (61.4) | 435 (75.9) | 138 (24.1) | 0.013 |
Female | 1373 (70.6) | 953 (69.4) | 1111 (80.9) | 262 (19.1) | |
Age groups, n (%) | |||||
Children | 41 (2.1) | 25 (61.0) | 31 (75.6) | 10 (24.4) | |
Adolescents | 105 (5.4) | 46 (43.8) | 56 (53.3) | 49 (46.7) | < 0.001 |
Adults | 1800 (92.5) | 1234 (68.6) | 1459 (81.1) | 341 (18.9) | |
Therapeutic regimen, n (%) | |||||
First line | 1841 (94.6) | 1261 (68.5) | 1471 (79.9) | 370 (20.1) | 0.037 |
Second line | 105 (5.4) | 44 (41.9) | 75 (71.4) | 30 (28.6) | |
ARV combination, n (%) | |||||
TDF + 3TC + EFV | 1070 (55.0) | 770 (72.0) | 890 (83.2) | 180 (16.8) | < 0.001 |
Other 1st line ARVc | 771 (39.6) | 491 (63.7) | 581 (75.4) | 190 (24.6) | |
ATVr or LPVr Based ARVd | 105 (5.4) | 44 (41.9) | 75 (71.4) | 30 (28.6) | |
Circumstance of diagnosis, n (%) | |||||
Consultation | 967 (49.7) | 625 (64.6) | 750 (77.6) | 217 (22.4) | < 0.001 |
Voluntary | 549 (28.2) | 396 (72.1) | 461 (84.0) | 88 (16.0) | |
PMTCT | 210 (10.8) | 153 (72.9) | 180 (85.7) | 30 (14.3) | |
At birth | 41 (2.1) | 22 (53.7) | 25 (61.0) | 16 (39.0) | |
Other/unknown | 179 (9.2) | 109 (60.9) | 130 (72.6) | 49 (27.4) | |
Urban vs rural, n (%) | |||||
Urban | 1737 (89.3) | 1171 (67.4) | 1388 (79.9) | 349 (20.1) | 0.004 |
Rural | 144 (7.4) | 98 (68.1) | 117 (81.2) | 27 (18.8) | |
Unknown | 65 (3.3) | 36 (55.4) | 41 (63.1) | 24 (36.9) | |